Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
Open Access
- 18 November 2020
- journal article
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (10), 3967
- https://doi.org/10.15829/1560-4071-2020-3967
Abstract
Aim. To study molecular biomarkers in patients with type 2 diabetes (T2D) in combination with heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF) and compare the data obtained with clinical characteristics of myocardial remodeling.Material and methods. The study included 42 patients with T2D (men — 53%, mean age — 60 years) with clinical manifestations of class II HF: 29 patients with HFpEF (group 1) and 13 patients with HFmrEF (group 2). The control group consisted of 13 healthy people, which were comparable in sex and age and had a normal body mass index (BMI). Patients received stable glucose-lowering and optimal drug therapy for HF for 3 months prior to enrollment in the study. Patients with HFpEF and HFmrEF were comparable in clinical and demographic parameters, had glycated hemoglobin (HbA ) of 8,5% and 8,8%, respectively (p>0,05), increased BMI or grade I-II obesity.We studied following biomarkers: NT-proBNP, highly sensitive C-reactive protein (hsCRP), sST2, galectin-3, procollagen type I C-terminal propeptide (PICP), matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1).Results. Volumetric parameters of the left ventricle (LV),LV mass indexed to growth and NT-proBNP were higher in the group of HFpEF patients (pConclusion. Patients with HFmrEF and T2D have higherLV volume and mass, higher concentrations of NT-proBNP and PICP in comparison with patients with HFpEF. The direction of MMP-9/TIMP-1 changes may reflect a decrease in antifibrotic processes. Further prospective studies on large samples using a multiple biomarker model are required in T2D and various HF phenotypes.Keywords
This publication has 30 references indexed in Scilit:
- Plasma matrix metalloproteinases in coronary artery disease patientsEuropean Journal of Clinical Investigation, 2015
- Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†Journal of the American Society of Echocardiography, 2015
- The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%)European Journal of Heart Failure, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of Invasive Cardiology, 2013
- Diabetic cardiomyopathy: pathophysiology and clinical featuresHeart Failure Reviews, 2012
- The fibrosis marker galectin‐3 and outcome in the general populationJournal of Internal Medicine, 2011
- N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.European Heart Journal – Cardiovascular Imaging, 2011
- Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemiaVideosurgery and Other Miniinvasive Techniques, 2011
- Circulating Biomarkers of Collagen Metabolism in Cardiac DiseasesJournal of the American College of Cardiology, 2010
- Cardiac Steatosis in Diabetes MellitusJournal of the American College of Cardiology, 2007